Novartis Sues Lupin To Protect Diovan Patent

Law360, New York (July 24, 2012, 1:57 PM EDT) -- Novartis Pharmaceuticals Corp. went after Lupin Ltd. in New Jersey federal court on Friday, accusing its pharmaceutical rival of infringing the patent used in hypertension treatment Diovan HCT in its attempts to market a competing generic version of the drug.

Novartis alleges Lupin is currently in the process of seeking regulatory approval from the Food and Drug Administration that would allow it to make and sell a Diovan HCT generic that would infringe a Novartis patent incorporated into the company's successful blood pressure drug.

The patent-in-suit...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.